Astellas Signs a ~$1.6M Research Collaboration with Dyno to Develop AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Shots:
- Dyno to receive an $18M up front & is eligible to receive additional payments during research, $235M in clinical & sales milestone along with royalties for resulting products with a total deal value of ~$1.6M
- The collaboration will combine Dyno’s AI-powered AAV vector engineering capabilities with Astellas gene therapies expertise in AAV-based pipeline assets to develop AAV vectors for gene therapy using Dyno’s CapsidMap platform
- Dyno will design novel AAV capsids with improved functional properties for gene therapy while Astellas will conduct preclinical, clinical &commercialization activities including manufacturing of gene therapy products using the novel capsids
Ref: Astellas | Image: Astellas
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com